Kidney function decline in the elderly: Impact of lipoprotein-associated phospholipase A2

American Journal of Nephrology

Volumn 34, Issue 6, 2011, Pages 512-518

  Peralta, Carmen A ^a,b,h   Katz, Ronit ^c   Shlipak, Michael ^a,b   Dubin, Ruth ^b   Deboer, Ian ^c   Jenny, Nancy ^d   Fitzpatrick, Annette ^c   Koro, Carol ^e   Kestenbaum, Bryan ^c   Ix, Joachim ^f   Sarnak, Mark ^g   Cushman, Mary ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF VERMONT   (United States)

^e GLAXOSMITHKLINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NONE   (United States)

Author keywords

Chronic kidney disease; Elderly; Estimated GFR; Kidney decline

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; CREATININE; CYSTATIN C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; AGING; ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RISK FACTOR;

EID: 80155213028     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000333045     Document Type: Article

References (35)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
2. Bibbins-Domingo K, Chertow GM, Fried LF, Odden MC, Newman AB, Kritchevsky SB, Harris TB, Satterfield S, Cummings SR, Shlipak MG: Renal function and heart failure risk in older black and white individuals: The Health, Aging, and Body Composition Study. Arch Intern Med 2006; 166: 1396-1402. (Pubitemid 44036352)
3. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS: Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237-246. (Pubitemid 46768607)
4. Shlipak MG, Katz R, Kestenbaum B, Fried LF, Siscovick D, Sarnak MJ: Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis 2009; 204: 298-303.
5. Keller C, Katz R, Sarnak MJ, Fried LF, Kestenbaum B, Cushman M, Shlipak MG: Inflammatory biomarkers and decline in kidney function in the elderly: The Cardiovascular Health Study. Nephrol Dial Transplant 2010; 25: 119-124.
6. Dubin R, Cushman M, Folsom AR, Fried LF, Palmas W, Peralta CA, Wassel C, Shlipak MG: Kidney function and multiple hemostatic markers: Cross sectional associations in the multi-ethnic study of atherosclerosis. BMC Nephrol 2011; 12: 3.
7. Upadhyay A, Larson MG, Guo CY, Vasan RS, Lipinska I, O'Donnell CJ, Kathiresan S, Meigs JB, Keaney JF Jr, Rong J, Benjamin EJ, Fox CS: Inflammation, kidney function and albuminuria in the Framingham Offspring Cohort. Nephrol Dial Transplant 2011; 26: 920-926.
8. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
9. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD: Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland coronary prevention study group. N Engl J Med 2000; 343: 1148-1155.
10. Suzuki T, Solomon C, Jenny NS, Tracy R, Nelson JJ, Psaty BM, Furberg C, Cushman M: Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: The Cardiovascular Health Study. Circ Heart Fail 2009; 2: 429-436.
11. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J: Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies. Lancet 2010; 375: 1536-1544.
12. Stafforini DM, Tjoelker LW, McCormick SP, Vaitkus D, McIntyre TM, Gray PW, Young SG, Prescott SM: Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem 1999; 274: 7018-7024.
13. Corson MA: Phospholipase A2 inhibitors in atherosclerosis: The race is on. Lancet 2009; 373: 608-610.
14. MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM: Lipoprotein- associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: Use of a novel inhibitor. Biochem J 1999; 338: 479-487.
15. Zalewski A, Macphee C: Role of lipoproteinassociated phospholipase A2 in atherosclerosis: Biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005; 25: 923-931. (Pubitemid 40627835)
16. Dubin R, Shlipak M, Li Y, Ix J, de Boer IH, Jenny N, Peralta CA: Racial differences in the association of pentraxin-3 with kidney dysfunction: The Multi-Ethnic Study of Atherosclerosis. Nephrol Dial Transplant 2011; 26: 1903-1908.
17. Peralta CA, Adeney KL, Shlipak MG, Jacobs D Jr, Duprez D, Bluemke D, Polak J, Psaty B, Kestenbaum BR: Structural and functional vascular alterations and incident hypertension in normotensive adults: The Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 2010; 171: 63-71.
18. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, et al: The Cardiovascular Health Study:Design and rationale. Ann Epidemiol 1991; 1: 263-276.
19. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
20. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD 3rd, Zhang YL, Greene T, Levey AS: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008; 51: 395-406. (Pubitemid 351273480)
21. Rifkin DE, Shlipak MG, Katz R, Fried LF, Siscovick D, Chonchol M, Newman AB, Sarnak MJ: Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 2008; 168: 2212-2218.
22. Kdoqi clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49:S12-S154.
23. Perkins BA, Nelson RG, Ostrander BE, Blouch KL, Krolewski AS, Myers BD, Warram JH: Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: Results of a 4-year follow-up study. J Am Soc Nephrol 2005; 16: 1404-1412. (Pubitemid 41716524)
24. Sarnak MJ, Katz R, Fried LF, Siscovick D, Kestenbaum B, Seliger S, Rifkin D, Tracy R, Newman AB, Shlipak MG: Cystatin C and aging success. Arch Intern Med 2008; 168: 147-153. (Pubitemid 351192910)
25. Shlipak MG, Katz R, Kestenbaum B, Fried LF, Newman AB, Siscovick DS, Stevens L, Sarnak MJ: Rate of kidney function decline in older adults: A comparison using creatinine and cystatin C. Am J Nephrol 2009; 30: 171-178.
26. Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, Palmas W, Siscovick D, Levey AS, Shlipak MG: Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 2011; 22: 147-155.
27. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP: Laboratory methods and quality assurance in the cardiovascular health study. Clin Chem 1995; 41: 264-270.
28. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle- aged men and women in the atherosclerosis risk in communities (ARIC) study. Circulation 2004; 109: 837-842. (Pubitemid 38252734)
29. Perticone F, Maio R, Perticone M, Sciacqua A, Shehaj E, Naccarato P, Sesti G: Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients. Circulation 2010; 122: 379-384.
30. Peralta CA, Jacob DR Jr, Katz R, Ix J, Madero M, Duprez D, Sarnak M, Criqui M, Kramer H, Palmas W, Herrington D, Shlipak M: The association of pulse pressure, arterial elasticity and endothelial function with kidney function decline among adults without chronic kidney disease: The Multi-Ethnic Study of Atherosclerosis. Am J Kidney Dis, in press.
31. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE: Predictors of the progression of renal disease in the modification of diet in renal disease study. Kidney Int 1997; 51: 1908-1919. (Pubitemid 27252762)
32. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ: Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities Study. Kidney Int 2000; 58: 293-301. (Pubitemid 30429874)
33. de Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick DS: 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol 2009; 20: 1805-1812.
34. Madder RD, Hickman L, Crimmins GM, Puri M, Marinescu V, McCullough PA, Safian RD: Validity of estimated glomerular filtration rates for assessment of baseline and serial renal function in patients with atherosclerotic renal artery stenosis: Implications for clinical trials of renal revascularization. Circ Cardiovasc Interv 2011; 4: 219-225.
35. Iribarren C, Gross MD, Darbinian JA, Jacobs DR Jr, Sidney S, Loria CM: Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: The CARDIA study. Arterioscler Thromb Vasc Biol 2005; 25: 216-221. (Pubitemid 40054279)